Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First head-to-head pivotal trial of ELVN-001

Next Previous
Trial Profile

First head-to-head pivotal trial of ELVN-001

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 18 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ELVN-001 (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Enliven Therapeutics

Most Recent Events

  • 13 Mar 2025 According to an Enliven Therapeutics media release, the company is focused on continued clinical execution and preparing for the potential start of a pivotal trial for ELVN-001 in 2026.
  • 23 Mar 2024 New trial record
  • 19 Mar 2024 According to an Enliven Therapeutics media release, company plans initial regulatory interactions with the aim of achieving regulatory path clarity regarding the first head-to-head pivotal trial by the end of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top